AstraZeneca’s Asthma Drug Tezspire Meets All Goals in Late-Stage Esophagitis Trial
The companies said the drug improved inflammation and swallowing symptoms in 368 patients, supporting a potential third indication for Tezspire.
- On Thursday, Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esophagitis .
- EoE affects more than 470,000 people in the U.S., with nearly half of patients failing to achieve adequate control with current first-line treatments including corticosteroids and proton pump inhibitors.
- The trial met co-primary endpoints at week 24, demonstrating statistically significant improvements in histologic remission and dysphagia symptoms among 368 enrolled patients; improvements were sustained through week 52.
- AstraZeneca reported $390 million in second-quarter Tezspire sales, a 45% jump compared to last year, with analysts describing the drug as a "meaningful growth driver" with "blockbuster potential."
- Ongoing Phase 3 JOURNEY and EMBARK trials continue investigating Tezspire's efficacy in chronic obstructive pulmonary disease, while the drug's success supports AstraZeneca's goal of $80 billion in annual sales by 2030.
12 Articles
12 Articles
AstraZeneca stated on Thursday (27) that its asthma medicine Tezspire achieved the main objectives of an advanced phase study in patients with a chronic inflammatory disorder of the esophagus, bringing good news to the company after a series of setbacks in its developing drug portfolio. The study showed that Tezspire, developed in partnership with Amgen, significantly reduced inflammation in the esophagus and relieved the difficulty of swallowin…
AstraZeneca said on Thursday its asthma drug Tezspire met the main goals of a late-stage trial in patients with a chronic inflammatory disorder of the oesophagus, offering the company a boost after a string of pipeline setbacks.
AstraZeneca’s asthma drug succeeds in late-stage oesophagitis trial
AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic oesophagitis, a chronic inflammatory disorder of the oesophagus
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
